Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2013-07-01 AGM Information
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
INNATE PHARMA : Assemblée Générale Mixte du 28 juin 2013
AGM Information Classification · 99% confidence The document is titled "ASSEMBLEE GÉNÉRALE MIXTE DU 28 JUIN 2013" (Mixed General Meeting of June 28, 2013) and reports on the outcomes of this meeting, specifically mentioning that all resolutions passed and announcing the appointment of a new member to the Supervisory Board (Conseil de Surveillance). This content directly relates to the proceedings and results of a shareholder meeting. The most appropriate classification among the provided options is AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (AGM). Although it also contains voting results, the overall context is the announcement summarizing the AGM event itself.
2013-07-01 French
INNATE PHARMA : nombre de droits de vote associés au 17 mai 2013
Share Issue/Capital Change Classification · 95% confidence The document is titled "NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 17 MAI 2013" and explicitly states it is published in accordance with French Commercial Code (Code de Commerce) and AMF (Autorité des marchés financiers) regulations. It details the total number of shares and voting rights as of a specific date (May 17, 2013). This type of mandatory disclosure regarding the total share capital and voting power is a specific regulatory filing, often related to capital structure changes or required periodic updates. While it relates to share capital, it is not a general financing announcement (CAP) or a transaction in own shares (POS), but rather a mandatory disclosure of the current count. Since it is a specific regulatory disclosure concerning share count and voting rights, and it doesn't fit perfectly into the other specific categories like DIRS (Director's Dealing) or MRQ (Major Shareholding Notification, which usually reports *changes* by an entity crossing a threshold), it falls best under the general regulatory announcement category, RNS, or potentially SHA (Share Issue/Capital Change) if interpreted broadly. However, given the context of mandatory disclosure of the total count based on AMF rules, and the lack of a specific 'Share Capital Count Disclosure' code, RNS (Regulatory Filings) serves as the most appropriate general regulatory fallback for this type of mandatory periodic disclosure that isn't a full report or a specific transaction notice. The document is short and is a direct announcement of data, not an announcement *of* a report.
2013-05-29 French
INNATE PHARMA : number of shares outstanding as well as its voting rights as at May 17, 2013
Share Issue/Capital Change Classification · 95% confidence The document is titled "NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT MAY 17, 2013" and explicitly states it is released pursuant to French commercial code and AMF regulations to disclose the total number of shares outstanding and voting rights. This type of mandatory disclosure regarding share capital structure and voting power, often released periodically or upon changes, fits best under categories related to capital structure or general regulatory announcements. Since it is not a dividend announcement (DIV), a major shareholding notification (MRQ, which usually reports *someone else's* holding crossing a threshold), or a general capital change (SHA, which usually announces an *issuance* or *split*), it is a specific regulatory disclosure. Given the options, this precise announcement about the current count of shares and voting rights is a specific regulatory filing. While it touches upon capital structure, it is primarily a mandatory disclosure of current share statistics. It is not a full report (10-K, IR), an earnings release (ER), or a management report (MDA). It is a specific regulatory update. Since there isn't a perfect fit for 'Share/Voting Rights Disclosure', the closest relevant categories are 'Major Shareholding Notification' (MRQ) if interpreted broadly as share structure changes, or the general 'Regulatory Filings' (RNS) as a fallback for specific, non-standard regulatory updates. Given the content is a direct calculation of total shares/rights based on regulatory requirements, and it is not a change in ownership threshold (MRQ), RNS is the most appropriate fallback for a specific, non-standard regulatory disclosure.
2013-05-29 English
Innate Pharma annonce la tenue de son assemblée générale annuelle le 28 juin 2013 à Marseille
AGM Information Classification · 98% confidence The document is titled "INNATE PHARMA ANNONCE LA TENUE DE SON ASSEMBLÉE GÉNÉRALE ANNUELLE LE 28 JUIN 2013 À MARSEILLE" (Innate Pharma announces the holding of its Annual General Meeting on June 28, 2013, in Marseille). It details the date, time, location, and procedural requirements (like voting procedures and document availability) for the upcoming Annual General Meeting (AGM). This content directly relates to the preparation and announcement of an AGM, fitting the definition for AGM Information (AGM-R). Although it announces the meeting, the content is substantial enough regarding the meeting logistics to be classified as AGM-R rather than just a brief RPA, as it contains specific shareholder instructions.
2013-05-28 French
Innate pharma to hold its annual general meeting of shareholders on june 28, 2013, in Marseille, France
AGM Information Classification · 98% confidence The document explicitly announces the date, time, and location for the 'ANNUAL GENERAL MEETING OF SHAREHOLDERS ("AGM")'. It details procedures for attendance, voting, and submitting questions related to this specific meeting. This content directly aligns with the definition of AGM Information, which is classified as 'AGM-R'. Although it mentions that the 'Notice of Meeting' was published, the core content is the announcement and details surrounding the AGM event itself, making AGM-R the most precise classification over a general RPA or RNS.
2013-05-28 English
INNATE PHARMA ANNOUNCES 1Q2013 REVENUE AND CASH IN LINE WITH EXPECTATIONS
Earnings Release Classification · 98% confidence The document is titled "INNATE PHARMA ANNOUNCES 1Q2013 REVENUE AND CASH IN LINE WITH EXPECTATIONS" and provides key financial figures (revenue of 2.7 million euros, cash position) for the first quarter of 2013. This structure strongly indicates an initial announcement of periodic financial results, which aligns with the definition of an Earnings Release (ER). Although it mentions the '2012 Reference Document' and 'Annual Financial Report' being available elsewhere, the primary content is the Q1 performance summary, not the comprehensive annual report itself. The document length (3395 chars) is short, but its content is a direct financial summary, not just an announcement *about* a report's publication (which would suggest RPA or RNS). Therefore, ER is the most appropriate classification. Q1 2013
2013-05-07 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.